🇺🇸 FDA

Drug profile · INN

bivalirudin

ANGIOX

approved B01AE06
US status
approved
Patents linked
3
News articles
0

Quick answer

bivalirudin (ANGIOX) is an FDA-listed pharmaceutical active ingredient. Associated with MAIA Biotechnology. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN bivalirudin
Brand ANGIOX
Route INJECTION
Formulation INJECTABLE
ATC code B01AE06
Originator MAIA Biotechnology

Related patents

Search patents →

  1. US 11992514

    Ready-to-use bivalirudin compositions

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11918622

    Ready-to-use bivalirudin compositions

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11903993

    Ready-to-use bivalirudin compositions

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is bivalirudin?

bivalirudin (ANGIOX) is an FDA-listed pharmaceutical active ingredient. Associated with MAIA Biotechnology. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for bivalirudin?

ANGIOX is a marketed brand name for bivalirudin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of bivalirudin?

bivalirudin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.